Rakovina Therapeutics Inc.
RKV.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 61.90% | 40.43% | 18.75% | 55.56% | -11.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.81% | 26.87% | 7.25% | 1.08% | -21.06% |
| Operating Income | -57.81% | -26.87% | -7.25% | -1.08% | 21.06% |
| Income Before Tax | -54.41% | -33.95% | -17.62% | -11.38% | 12.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.41% | -33.95% | -17.62% | -11.38% | 12.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.41% | -33.95% | -17.62% | -11.38% | 12.10% |
| EBIT | -57.81% | -26.87% | -7.25% | -1.08% | 21.06% |
| EBITDA | -75.48% | -35.36% | -8.78% | -1.44% | 25.25% |
| EPS Basic | -20.29% | -32.81% | -17.65% | -11.76% | 12.66% |
| Normalized Basic EPS | -20.93% | -32.50% | -19.05% | -11.63% | 12.24% |
| EPS Diluted | -10.67% | -14.86% | -8.11% | -11.76% | 5.06% |
| Normalized Diluted EPS | -20.93% | -32.50% | -19.05% | -11.63% | 12.24% |
| Average Basic Shares Outstanding | 28.45% | 1.29% | 0.37% | 0.11% | -0.03% |
| Average Diluted Shares Outstanding | 28.45% | 1.29% | 0.37% | 0.11% | -0.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |